Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.

Also called NCT01680341

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 272 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01680341
  • EudraCT 2012-000373-23
Other papers using this trial's data
  • Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial Diabetic medicine : a journal of the British Diabetic Association, 2013-11 DOI, PubMed 23710902, PMC4264937 In the PMC Open Access subset under CC BY-NC-ND.
  • TREATMENT INTENSIFICATION WITH INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY: RANDOMIZED STUDY TO COMPARE SIMPLE AND STEP-WISE TITRATION ALGORITHMS Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2016-05 DOI, PubMed 26720250

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Algeria, Germany, Malaysia, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01680341. Randomized; no masking; primary purpose treatment. Start 2012-08-31 (actual); primary completion 2013-08-22 (actual). Results posted on 2015-11-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine
Acronym
BOOST®
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec/insulin aspart
Intervention (Drug)
insulin degludec/insulin aspart
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01680341
Content hash
bdd2abba908791a8050e6f357798565ea2859ff46db22ed521a250962f646921